4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Neuland Laboratories Limited (NEULANDLAB) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Hyderabad, India with about 2,183 employees. Its market capitalization is roughly ₹293 billion. In the fiscal year ended 2026-03-31, NEULANDLAB reported ₹19.3B in revenue and ₹3.6B in net income.
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services.
Interactive charts & full statements →
| Income statement | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Total Revenue | ₹19.3B | ₹14.3B | ₹15.2B | ₹11.6B |
| Gross Profit | ₹9.8B | ₹6.8B | ₹7.8B | ₹5.5B |
| Operating Income (EBIT) | ₹4.9B | ₹2.7B | ₹4.1B | ₹2.3B |
| Net Income | ₹3.6B | ₹2.6B | ₹3.0B | ₹1.6B |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Total Revenue | ₹6.4B | ₹7.8B | ₹4.4B | ₹5.1B | ₹2.9B | — |
| Gross Profit | ₹3.7B | ₹4.6B | ₹2.0B | ₹2.8B | ₹1.4B | — |
| Operating Income (EBIT) | ₹2.0B | ₹2.8B | ₹532M | ₹1.3B | ₹143M | — |
| Net Income | ₹1.5B | ₹2.1B | ₹406M | ₹968M | ₹139M | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Dividends Paid | (₹154M) | (₹180M) | (₹128M) | (₹64M) | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Assets | ₹29.3B | ₹21.8B | ₹18.3B | ₹15.8B | — |
| Total Liabilities | ₹10.6B | ₹6.6B | ₹5.5B | ₹5.9B | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NEULANDLAB viewer.
This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी
About TickerBase · Data methodology & sources · Privacy · Terms